FLGT News and Press, Fulgent Genetics Inc. From 04/11/23

2023-04-11 10:05:56 ET Fulgent Genetics ( NASDAQ: FLGT ) and Mission Bio are collaborating to broaden accessibility of single-cell multi-omics for drug development and clinical research. Fulgent said it is now able to offer single-cell multi-omics on the Tapestri Platform...

Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research PR Newswire Strategic partnership between Mission Bio and Fulgent Genetics will enable drug developers to leverage single-cell multi-omics ...

Fulgent Genetics, Inc. (FLGT) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer ...

Fulgent Genetics press release ( NASDAQ: FLGT ): Q4 Non-GAAP EPS of -$0.48 beats by $0.08 . Revenue of $67.7M (-73.1% Y/Y) beats by $8.13M . Core Revenue grew 97% year-over-year to $55.0 million For the first quarter of 2023, Fulgent expects: Total Reve...

Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the ...

New 787 gene panel becomes the largest panel available on Fulgent Genetics’ platform, setting a new standard for patients seeking the most comprehensive option for carrier screening Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a ...

Fulgent Genetics ( NASDAQ: FLGT ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.56 (vs. $3.48 last year) and the consensus Revenue Estimate is $59.57M (-76.3% Y/Y). Over the last 2 years, FLGT ha...

Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Ra...

Summary Today, we revisit Fulgent Genetics. The company continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. However, 'core' testing sales are seeing impressive growth and the company has a massive amount of cash on its balance sheet. An u...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that it w...